Perhexiline, a chiral drug, is a potent antiischemic agent whose clinical utility is limited by hepatic and neural toxicities. It inhibits mitochondrial carnitine palmitoyltransferase-1, however, excessive inhibition predisposes toward tissue steatosis.
| INTRODUCTION
In Australia, perhexiline is approved for treating patients with refractory angina pectoris or patients with angina in whom other therapies are contraindicated. 1 However, it also has other clinically beneficial effects, including enhancing myocardial energetics, in heart failure 2 and hypertrophic cardiomyopathy, 3 and improving New York Heart Association functional class in inoperable aortic stenosis. 4 Perhexiline inhibits carnitine palmitoyltransferase 1 (CPT-1), 5 the enzyme that initiates mitochondrial translocation of free fatty acids, the rate-limiting step for their b-oxidation. Inhibition of CPT-1 (and b-oxidation), facilitates the utilization of carbohydrates, 6 thus maintaining myocardial production of ATP with lower oxygen consumption. 7 Although deficient myocardial energetics are increasingly recognized as an underlying feature of cardiovascular disease, 7 the potential for perhexiline to cause hepatotoxicity and peripheral neuropathy has limited its clinical use for extended exposures. 8, 9 Both adverse effects have been associated with altered lipid storage, including steatosis and lysosomal phospholipidosis, which may reflect excessive CPT-1 inhibition, as previously described with other drugs. 10 Although current clinical practice incorporating therapeutic monitoring of perhexiline in plasma has practically abolished the risk of hepatic and neural toxicity, 11, 12 it remains a major impediment to wider clinical use.
Perhexiline, a chiral compound, is on the market as a racemic mixture, with no data on the pharmacology of the individual enantiomers, and only pharmacokinetic investigations of the enantiomers, particularly their extensive metabolism by cytochrome P450 2D6 (CYP2D6). [13] [14] [15] The female Dark Agouti (DA) rat, traditionally an animal model for the human CYP2D6 poor metabolizer phenotype, has previously been utilized to investigate the hepatic and neural toxicity of racemic perhexiline. 16, 17 17 The animals' average daily food pellet consumption had been calculated over a 5-day period prior to commencement of the dosing study. At the end of week 4, blood was collected from the tail vein, and plasma was separated and stored at À20°C. On the day of the final week 8 dose, Von Frey filament testing was used to assess peripheral neural function. 19 The next morning, blood was collected under anesthesia, via a cardiac puncture, and plasma was separated and stored at À20°C. After being euthanized, the liver, heart and neuronal tissues were harvested. Tissues were divided, with part snap frozen immediately in liquid nitrogen, some placed into a solution of fixative for subsequent electron microscopy and the remainder paraffin embedded for hematoxylin and eosin (H&E) staining.
Due to the small quantity of (+)-perhexiline maleate available, one of the four animals was treated for only 4 weeks. The plasma concentration data for this animal were still used for pharmacokinetic analyses, assuming pharmacokinetic steady state had been attained.
However, we could not assume that pharmacodynamic effects had reached steady state and it was omitted from week 8 analyses of histology, neuronal function or plasma biochemistry (see below).
| Hepatic and neuronal morphology
Gross hepatic morphology was assessed, using formalin-fixed, paraffin-embedded 6 lm H&E stained sections. Hepatic and neuronal tissues (approximately 0.5 mm 3 ) were also processed for analysis by transmission electron microscopy as previously described. 17 For liver electron micrographs, lipid vesicles, and glycogen were identified 20 and total content measured as a percentage of the field of view using Image J software (http://imagej.
nih.gov/ij/). The average content was calculated from examining two to three de-identifed sections of each tissue. To confirm histological assessment of glycogen content, biochemical analysis was also performed using stored frozen hepatic tissue, as described by Unger et al. 21 Neuronal sections were assessed for the presence of Mallory bodies. were combined to establish a normal range (n = 8), and hepatotoxicity was defined as values >1.5-times above the upper limit of normal, or values below the lower limit of normal for albumin.
| Quantitation of perhexiline and its OHmetabolites
Heart and liver homogenates were prepared, using 0.15 mol/L phosphate buffer at pH 7.4 (2 mL per g of tissue, on ice) and stored (À80°C) pending analysis. The concentrations of (+)-and (À)-perhexiline in plasma and homogenates of heart or liver were measured by high performance liquid chromatography, 18 as were the concentrations of cis-, trans1-and trans2-OH-perhexiline in plasma and liver homogenate. 22 The lower limit of quantification for parent enantiomers and the metabolites was 0.01 mg/L. 3 | RESULTS
| Statistical analyses

| Perhexiline concentrations
Concentrations of the enantiomers and their metabolites in plasma and tissue are presented in Table 1 . The ratio of (+)-to (À)-enantiomers in plasma was approximately 2:1 regardless of whether animals were administered the individual enantiomers or racemate. Figure 1 shows the plasma and tissue concentrations of (+)-and (À)-perhexiline normalized to an enantiomeric dose of 100 mg/kg per day. No difference was observed in the dose-adjusted concentrations of (+)-perhexiline in plasma between enantiomeric and racemic administrations. Similarly, (À)-perhexiline also displayed dose-independent plasma pharmacokinetics.
For both enantiomers, the concentrations in tissue (heart or liver) were at least 20-times greater than the corresponding concentrations in plasma ( Figure 1B ) and, similar to plasma, tissue (+)-perhexiline concentrations were generally higher than those of (À)-perhexiline ( Figure 1A ). However, when pure enantiomers were administered, the concentrations of (+)-perhexiline in the two tissues were 6 to 10 times higher than (À)-perhexiline (P < .05), and the tissue (heart or liver):plasma concentration ratios for (+)-perhexiline were also significantly higher than (À)-perhexiline (P < .05) ( Figure 1B ). In contrast, following administra- 
| OH-metabolite concentrations
The formation of cisÀ and trans-mono-hydroxy metabolites is shown in Table 1 . Cis-OH-perhexiline was the most abundant metabolite lmol/g tissue, respectively P < .05).
| Neural function and histology
Peripheral neural function assessed as paw withdrawal threshold in the Von Frey test is shown in Figure 3C . All of the animals treated 
| DISCUSSION
It is increasingly apparent that perhexiline's inhibition of CPT-1 may not sufficiently account for its improvement of myocardial function. 21 Other mechanisms may be important also, such as sensitizing the response to nitric oxide and its anti-inflammatory properties. 21, 23, 24 Perhexiline's mechanisms of action have remained poorly reported for (AE)-perhexiline in animals 16 and humans. 26 Indeed, in this study, both total and individual enantiomer concentrations in plasma and heart following administration of the racemate to rats were similar to those observed clinically. 26, 27 Although there was no evidence of substantial enantioselectivity in the in vivo uptake of perhexiline into human myocardium following clinical administration of racemate, 27 this current study has revealed significant enantioselectivity in the hepatic and myocardial distribution of (+)-and (À)-perhexiline, but it was evident only following administration of the pure enantiomers.
Since the apparent oral clearance of each enantiomer in DA rats was unaffected by the dosage form administered (enantiomer or 
